CY1114777T1 - Αδενοϊικοι κομιστες που εκφραζουν ιντερλευκινη-12 μονης αλυσιδας και 4-1ββ συνδετη - Google Patents

Αδενοϊικοι κομιστες που εκφραζουν ιντερλευκινη-12 μονης αλυσιδας και 4-1ββ συνδετη

Info

Publication number
CY1114777T1
CY1114777T1 CY20131101171T CY131101171T CY1114777T1 CY 1114777 T1 CY1114777 T1 CY 1114777T1 CY 20131101171 T CY20131101171 T CY 20131101171T CY 131101171 T CY131101171 T CY 131101171T CY 1114777 T1 CY1114777 T1 CY 1114777T1
Authority
CY
Cyprus
Prior art keywords
single chain
adenoviral
compressors
connector
expressing interleukin
Prior art date
Application number
CY20131101171T
Other languages
English (en)
Inventor
Reinhard WÄHLER
Frank Schnieders
Original Assignee
Provecs Medical Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provecs Medical Gmbh filed Critical Provecs Medical Gmbh
Publication of CY1114777T1 publication Critical patent/CY1114777T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ιικούς κομιστές που περιλαμβάνουν αλληλουχίες νουκλεϊκού οξέος οι οποίες κωδικεύουν ιντερλευκίνη-12 μονής αλυσίδας (ΙL-12 μονής αλυσίδας, "single chain ΙL-12" ή sclL12) και πρωτεΐνη-συνδιεγέρτη, καθώς και στην χρήση αυτών των κομιστών για γονιδιοθεραπεία, ιδίως για την θεραπεία όγκων. Η εφεύρεση σε περαιτέρω επίπεδο αναφέρεται σε αδενοϊικούς κομιστές που περιέχουν αλληλουχίες νουκλεϊκού οξέος οι οποίες εμφανίζουν ομολογία αλληλουχίας τουλάχιστον 90% προς την αλληλουχία που δείχνεται στα σχήματα 19 και 20 (ΙL-12), στο σχήμα 21 (4-1ΒΒ συνδέτης) και στο σχήμα 22 (ΙL-2) και ενίοτε σε περαιτέρω επίπεδο μία των αλληλουχιών που δείχνονται στο σχήμα 23Α (Β7-1) ή 23Β (Β7-2).
CY20131101171T 2002-10-11 2013-12-27 Αδενοϊικοι κομιστες που εκφραζουν ιντερλευκινη-12 μονης αλυσιδας και 4-1ββ συνδετη CY1114777T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10248141A DE10248141B4 (de) 2002-10-11 2002-10-11 Nukleinsäuren und deren Verwendung für die Gentherapie
EP03757951.3A EP1556411B1 (de) 2002-10-11 2003-10-10 Adenovirale Vektoren die Einzelketten Interleukin-12 und 4-1BB Ligand exprimieren

Publications (1)

Publication Number Publication Date
CY1114777T1 true CY1114777T1 (el) 2016-12-14

Family

ID=32102775

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131101171T CY1114777T1 (el) 2002-10-11 2013-12-27 Αδενοϊικοι κομιστες που εκφραζουν ιντερλευκινη-12 μονης αλυσιδας και 4-1ββ συνδετη

Country Status (11)

Country Link
US (1) US8067227B2 (el)
EP (1) EP1556411B1 (el)
JP (2) JP4615311B2 (el)
AU (1) AU2003273983A1 (el)
CY (1) CY1114777T1 (el)
DE (1) DE10248141B4 (el)
DK (1) DK1556411T3 (el)
ES (1) ES2440951T3 (el)
PT (1) PT1556411E (el)
SI (1) SI1556411T1 (el)
WO (1) WO2004035799A2 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069272A2 (en) * 2003-02-05 2004-08-19 Movecare Ltd Adjuvant combination for use in the immunization of a mamal comprising il2 and il12
DE102005055128B4 (de) * 2005-11-15 2015-04-02 Universität Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
CN102174479B (zh) * 2011-03-02 2013-04-03 北京锤特生物科技有限公司 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
JP6489353B2 (ja) 2011-10-11 2019-03-27 ウニヴェルズィテート チューリッヒ 腫瘍療法のためのｉｌ−１２とｔ細胞阻害分子遮断薬とを含む医薬組成物
ES2753259T3 (es) 2015-04-22 2020-04-07 Curevac Ag Composición que contiene ARN para el tratamiento de enfermedades tumorales
KR20190031424A (ko) * 2015-12-18 2019-03-26 온코섹 메디컬 인코포레이티드 이종 단백질 발현을 위한 플라스미드 작제물 및 사용 방법
EP3211000B1 (en) * 2016-02-25 2019-01-30 Provecs Medical GmbH Novel immunostimulating vector system
LT3458083T (lt) 2016-05-18 2023-02-10 Modernatx, Inc. Polinukleotidai, koduojantys interleukiną-12 (il12), ir jų naudojimas
AU2018229278A1 (en) 2017-02-28 2019-10-17 Sanofi Therapeutic RNA
JP7165680B2 (ja) 2017-05-02 2022-11-04 ネクター セラピューティクス 免疫療法的腫瘍治療方法
JP7074864B2 (ja) * 2018-01-19 2022-05-24 コーロン ライフ サイエンス インコーポレイテッド 組換えワクシニアウイルスおよびそれを含む医薬組成物
US11230699B2 (en) * 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
WO2000041508A2 (en) 1999-01-15 2000-07-20 Mount Sinai School Of Medicine Of The City University Of New York Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines
KR20020010206A (ko) * 2000-07-27 2002-02-04 이시우 인터루킨 12와 보조활성인자 ｂ7.1 유전자를 함유하는ｄｎａ 벡터 및 이벡터가 도입된 항암 세포백신
EP2336339A3 (en) * 2000-09-25 2011-09-14 The Regents of the University of Michigan Production of viral vectors

Also Published As

Publication number Publication date
ES2440951T3 (es) 2014-01-31
SI1556411T1 (sl) 2014-01-31
AU2003273983A1 (en) 2004-05-04
EP1556411B1 (de) 2013-10-02
DK1556411T3 (da) 2014-01-20
WO2004035799A3 (de) 2004-06-10
DE10248141B4 (de) 2007-04-19
EP1556411A2 (de) 2005-07-27
US20060153805A1 (en) 2006-07-13
DE10248141A1 (de) 2004-09-02
PT1556411E (pt) 2014-01-07
JP4615311B2 (ja) 2011-01-19
JP2006511212A (ja) 2006-04-06
AU2003273983A8 (en) 2004-05-04
US8067227B2 (en) 2011-11-29
WO2004035799A2 (de) 2004-04-29
JP2011036251A (ja) 2011-02-24

Similar Documents

Publication Publication Date Title
CY1114777T1 (el) Αδενοϊικοι κομιστες που εκφραζουν ιντερλευκινη-12 μονης αλυσιδας και 4-1ββ συνδετη
CY1121113T1 (el) Θεραπεια της νοσου ρομρε
FI961755A0 (fi) Yhdistelmäadenovirusvektori ja menetelmiä sen käyttämiseksi
NO20004631L (no) Forbindelser og fremgangsmÕter for terapi og diagnose av lungekreft
HK1065826A1 (en) Vaccinia virus for diagnosis and therapy of tumors
DK2014678T3 (da) KDR-peptider og vacciner indeholdende disse
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
IL231502A0 (en) Simian adenoid virus nucleic acid and amino acid sequences, vectors containing the same and methods of use
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
HK1049848A1 (zh) 用於治療和診斷肺癌的化合物和方法
DE69924826T8 (de) Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
IL199127A (en) Promoters for expression in modified vaccinia virus ankara (mva) and vectors comprising said promoters
DK1536006T3 (da) Cancerantigener og anvendelse deraf
ATE371031T1 (de) Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
GB0118532D0 (en) Materials and methods relating to improved vaccination strategies
DK1147212T3 (da) T-hjælpecelle-epitoper
DE69426121D1 (de) Gen grb3-3, variante und ihre verwendungen
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
EP2149381A3 (en) Method of treating malignancies through induction of blood immune responses
DE602004001047D1 (de) Phospholipidester von Clofarabin
ATE304593T1 (de) Menschliches gen und protein eines magenkrebs- antigens
ATE210990T1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
Dowell Rescue in Sudan.